Chromosomal Aberrations in Polycythemia Vera

Chromosomal aberrations in polycythemia vera.

By B. MODAN, B. PADEH, H. KALLNER, E. Axsr IN, D. MEYTES, P. CZERNIAK, B. RAMOT, J. PINKHAS AND M. MODAN T HE RELATIVELY HICH RISK of developing leukemia in the course of polycythemia vera ( PV ) , and the presence of both specific and nonspecific chromosomal aberrations in patients with myeloprohferative disorders,25 led us to undertake a prospective follow-up study of patients with PV. In thi...

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b

Fifty-one polycythemia vera (PV) patients were enrolled in the phase I/II clinical study PEGINVERA to receive a new formulation of pegylated interferon alpha (peg-proline-IFNα-2b, AOP2014/P1101). Peg-proline-IFNα-2b treatment led to high response rates on both hematologic and molecular levels. Hematologic and molecular responses were achieved for 46 and 18 patients (90 and 35% of the whole coho...

Muramidase in polycythemia vera.

Erythropoietin receptors in polycythemia vera.

The role of erythropoietin (EP) in polycythemia vera (PV) is controversial, with some experiments suggesting that erythroid progenitors in PV are exquisitely sensitive to EP and EP dependent, and others suggesting that PV progenitors are EP independent. We have examined the characteristics of the EP receptor (EP-R) on erythroid colony-forming cells (ECFC) from patients with PV. In contrast to n...

Treatment of polycythemia vera.

BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...